Suppr超能文献

WHIM 综合征的基因型-表型相关性:CXCR4 变异的系统特征分析。

Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4 variants.

机构信息

X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria.

X4 Pharmaceuticals Inc, Boston, MA, USA.

出版信息

Genes Immun. 2022 Sep;23(6):196-204. doi: 10.1038/s41435-022-00181-9. Epub 2022 Sep 12.

Abstract

Warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome is a rare primary immunodeficiency predominantly caused by heterozygous gain-of-function mutations in CXCR4 C-terminus. We assessed genotype-phenotype correlations for known pathogenic CXCR4 variants and in vitro response of each variant to mavorixafor, an investigational CXCR4 antagonist. We used cell-based assays to analyze CXCL12-induced receptor trafficking and downstream signaling of 14 pathogenic CXCR4 variants previously identified in patients with WHIM syndrome. All CXCR4 variants displayed impaired receptor trafficking, hyperactive downstream signaling, and enhanced chemotaxis in response to CXCL12. Mavorixafor inhibited CXCL12-dependent signaling and hyperactivation in cells harboring CXCR4 mutations. A strong correlation was found between CXCR4 internalization defect and severity of blood leukocytopenias and infection susceptibility, and between AKT activation and immunoglobulin A level and CD4 T-cell counts. This study is the first to show WHIM syndrome clinical phenotype variability as a function of both CXCR4 genotype diversity and associated functional dysregulation. Our findings suggest that CXCR4 internalization may be used to assess the pathogenicity of CXCR4 variants in vitro and also as a potential WHIM-related disease biomarker. The investigational CXCR4 antagonist mavorixafor inhibited CXCL12-dependent signaling in all tested CXCR4-variant cell lines at clinically relevant concentrations.

摘要

疣、低丙种球蛋白血症、感染、骨髓嗜中性粒细胞减少症(WHIM)综合征是一种罕见的原发性免疫缺陷病,主要由 CXCR4 羧基末端的杂合获得性功能突变引起。我们评估了已知致病性 CXCR4 变体的基因型-表型相关性,并研究了每种变体对研究性 CXCR4 拮抗剂 mavorixafor 的体外反应。我们使用基于细胞的测定法分析了 14 种先前在 WHIM 综合征患者中发现的致病性 CXCR4 变体在 CXCL12 诱导的受体运输和下游信号转导中的作用。所有 CXCR4 变体均显示出受损的受体运输、过度活跃的下游信号转导以及对 CXCL12 的增强趋化性。mavorixafor 抑制了携带 CXCR4 突变的细胞中 CXCL12 依赖性信号转导和过度激活。发现 CXCR4 内化缺陷与血液白细胞减少症和感染易感性的严重程度之间以及 AKT 激活与免疫球蛋白 A 水平和 CD4 T 细胞计数之间存在很强的相关性。这项研究首次表明,WHIM 综合征的临床表型变异性是 CXCR4 基因型多样性和相关功能失调的共同作用。我们的研究结果表明,CXCR4 内化可用于体外评估 CXCR4 变体的致病性,也可作为潜在的与 WHIM 相关的疾病生物标志物。在临床相关浓度下,研究性 CXCR4 拮抗剂 mavorixafor 抑制了所有测试的 CXCR4 变体细胞系中 CXCL12 依赖性信号转导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4ca/9519442/b5d8a466fb0a/41435_2022_181_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验